The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

Thu, 04th Apr 2024 17:24

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Artemis Resources Ltd - gold, copper and lithium-focused exploration company with projects in Western Australia - Updates on Karratha gold project exploration programme in West Pilbara, Western Australia. Says Lulu Creek will be drill tested in the third quarter of 2024. Adds that programme of works is submitted and approved, with heritage clearance application underway.

----------

Develop North PLC - investor in residential and commercial property sector - Starts share buyback programme of up to GBP500,000. The programme is set to end on June 30 and could be terminated earlier.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Raises GBP51,670 via issuing 5.2 million retail offer shares at a price of 1 pence each. Applies to the London Stock Exchange for the admission of a total of 152.5 million new shares to trading on AIM, comprising of 79.4 million placing shares, 5.6 million subscription shares and 62.3 million initial consideration shares

----------

Genflow Biosciences PLC - London-based biotechnology company focused on longevity - Raises GBP715,000 via its broker Capital Plus Partners by placing 57.2 million shares. Chief Executive Officer Eric Leire invested GBP50,000 personally in the placing, the company says.

----------

Insig AI PLC - London-based data science and machine learning firm - Agrees to a GBP250,000 equity funding facility with Executive Chair Richard Bernstein, which will allow him to subscribe for up to around 1.3 million new shares at 20 pence per share until the end of August.

----------

Northcoders Group PLC - Manchester-based software coding training provider - Launches part-time business-to-costumer software development bootcamp that aims to make careers in tech more accessible. The virtual course will start in mid-July and has been created due to demand for alternative structures, Northcoders says. Chief Executive Officer Chris Hill says: "Not only is this in line with the group's strategy to address the nation's widening digital skills, but it embodies our commitment to inclusivity and flexibility, ensuring that anyone who is interested in the opportunity to work in the ever-growing UK technology market can pursue their ambitions, regardless of their schedule or background."

----------

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Raises GBP1.2 million via issuing 11.7 million fundraising shares at the placing price of 10p per share.

----------

Schroder BSC Social Impact Trust PLC - investment firm focused on positive social impact as well as long-term capital growth and income - Announces GBP5 million commitment to Savills IM Simplify Affordable Homes Ltd Partnership, which will lie within Schroder's High Impact Housing asset class allocation. "The UK continues to face a housing crisis with an acute lack of social and affordable housing and this fund will deliver homes for lower income households and people currently in need of social housing in areas in most need. The SAH management team have a strong track record, with over 30 years' expertise and deep sector knowledge with long standing housing association relationship. We believe they are well-placed to deliver high quality financial and impact returns through providing affordable housing at-scale," says Jeremy Rogers, chief investment officer of Big Society Capital, portfolio manager of Schroder BSC.

----------

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.